CERNAIS Selected for the INNOVIT Life Sciences & Biotech Program in San Francisco

CERNAIS is proud to announce its selection for the INNOVIT Life Sciences & Biotech Program, an international acceleration initiative connecting high-potential Italian startups with the Silicon Valley innovation ecosystem.

CERNAIS was ranked among the top startups selected for the 2026 cohort.

INNOVIT – Italian Innovation and Culture Hub – is a strategic initiative promoted by the Italian Ministry of Foreign Affairs and International Cooperation together with the Italian Consulate General in San Francisco. The program supports Italian innovation through mentorship, investor engagement, business development, and direct engagement with the U.S. startup and biotech ecosystem.

As part of the program, CERNAIS will participate in an intensive acceleration pathway including pitch coaching, mentorship sessions, networking opportunities, one-to-one meetings with investors and industry leaders, and a final Demo Day in San Francisco.

CERNAIS is developing AI-driven RNA-based therapeutic approaches for neurological and rare diseases, with the goal of accelerating the discovery of precision medicines for patients with limited treatment options.

The selection represents an important milestone in CERNAIS’ international growth strategy and reinforces the company’s commitment to advancing next-generation biotech innovation through science, artificial intelligence, and translational research.

CERNAIS would like to thank the INNOVIT team and organizers for this opportunity and looks forward to engaging with the broader innovation community in Silicon Valley.